Four analysts raise Pfizer targets. Pfizer stock gains 1.48 percent

Published on 10/12/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 15.03 billion versus USD 14.40 billion consensus. Pfizer stock costs EUR 25.35 on October 12, 2026 versus EUR 24.98.

Key points in brief

Four Wall Street firms raised Pfizer price targets between October 6 and October 9, 2026.
Second-quarter 2026 revenue reached USD 15.03 billion versus USD 14.40 billion consensus.
Pfizer stock was at EUR 25.35 at Lang & Schwarz on October 12, 2026, plus 1.48 percent versus the Xetra close of October 9, 2026 at EUR 24.98.
Full-year 2026 revenue guidance rose to USD 60.5 billion-USD 62.5 billion from USD 59.5 billion-USD 60.5 billion.

Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA, Symbolbild für Pfizer Inc — Geometrisches Bauhaus-Poster mit dem Wort PHARMA visualisiert die Branche von Pfizer Inc., ISIN US7170811035, künstlerisch, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was at EUR 25.35 at Lang & Schwarz on October 12, 2026 at 11:59 a.m. CEST, up 1.48 percent versus the Xetra close of October 9, 2026 at EUR 24.98. Four Wall Street firms raised Pfizer price targets between October 6 and October 9, while ratings stayed unchanged, according to Yahoo Finance on October 10, 2026.

Four targets moved higher

JPMorgan lifted its target to USD 30.00 from USD 28.00, Bank of America raised its target to USD 29.00 from USD 27.00, and Cantor Fitzgerald moved to USD 28.00 from USD 27.00. Scotiabank raised its target to USD 33.00 from USD 30.00 and kept an Outperform rating, according to Yahoo Finance.

The target revisions followed Pfizer's second-quarter performance. Yahoo Finance reported that second-quarter 2026 revenue was USD 15.03 billion, up 1.00 percent operationally year over year, while adjusted diluted earnings per share reached USD 0.77.

What does guidance mean for growth?

Pfizer raised the midpoint of its full-year 2026 revenue guidance by USD 500.0 million to USD 60.5 billion-USD 62.5 billion from USD 59.5 billion-USD 60.5 billion, according to Yahoo Finance. Adjusted diluted earnings per share guidance remained USD 2.80-USD 3.00, with management citing a USD 650.0 million acquired in-process research and development charge linked to the Innovent Biologics transaction.

The operating picture is mixed. Launched and acquired products generated USD 3.2 billion in second-quarter 2026 revenue and grew 18.00 percent operationally, while Pfizer's adjusted operating margin was 35.00 percent, according to Yahoo Finance. The guidance increase therefore rests on the non-COVID portfolio while COVID product revenue expectations were reduced.

Three dated Pfizer milestones

On August 4, 2026, Pfizer reported second-quarter revenue of USD 15.03 billion and adjusted diluted earnings per share of USD 0.77, according to Yahoo Finance. On October 6, 2026, Scotiabank raised its price target to USD 33.00 from USD 30.00, as reported by Markets Insider. On October 10, 2026, Yahoo Finance summarized four target increases across the week.

Next reporting date

Pfizer's next report covers the third quarter of 2026 and is scheduled for November 3, 2026, according to Yahoo Finance. The date gives investors a defined checkpoint for testing whether the raised revenue outlook is translating into operating performance.

Stock trades above the Xetra close

Pfizer's EUR 25.35 quote at Lang & Schwarz was 1.48 percent above the Xetra close of October 9, 2026 at EUR 24.98. On the NYSE, Pfizer was last at USD 28.28 on October 9, 2026 at 4:01 p.m. ET, while its 52-week range was USD 23.62-USD 29.21.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.